Hainan Yedao, once the undisputed pioneer of China’s medicinal wine sector, now finds itself teetering on the edge of a forced exit from the Shanghai Stock Exchange. For this veteran brand, the difference between survival and delisting hinges on a single, audited figure: whether its 2025 revenue can stay above the 300 million RMB (US$41 million) "survival line." While the company’s preliminary results suggest a safe margin of 350 million RMB, a deeper look into the books reveals a house of cards that regulators are beginning to dismantle.
The core of the controversy lies in the "Lugui Wine Jiapin" series, a product line launched late in 2025 that miraculously accounted for over half of the company’s total liquor revenue. Despite the impressive top-line numbers, auditors discovered that as of early 2026, only a fraction of these goods had actually reached consumers. The vast majority of the "sold" inventory remains sitting in distributor warehouses, raising serious questions about whether these sales represent genuine market demand or strategic channel-stuffing to meet listing requirements.
Further scrutiny has uncovered a bizarre pattern among the company's top clients. Several of Hainan Yedao's major distributors were registered just months before the 2025 year-end and immediately began placing multimillion-RMB orders. These "pop-up" entities, often lacking prior industry history or transparent ownership, have become the primary pillars of the company’s revenue growth. This concentration of new, high-volume customers in the final quarter of the year is a classic red flag for regulators monitoring "revenue manufacturing."
The fall of Hainan Yedao serves as a cautionary tale of corporate overreach and strategic drift. In the early 2000s, the brand was a household name, rivaling industry giants like Jing Wine. However, decades of shifting focus between real estate, trading, and various liquor segments diluted its brand equity and drained its resources. A high-stakes gamble on the "sauce-aroma" liquor craze in 2021 further crippled the company, leading to massive losses and internal governance collapses.
Even if the revenue threshold is technically met, the company remains at the mercy of its auditors regarding internal controls. Hainan Yedao has a history of missing shipment records, undocumented returns, and "negative" opinions on its management practices. If the 2025 audit results in another non-standard opinion, the "First Health Wine" stock will likely see its decades-long run on the public market come to a final, ignominious end.